# Ningbo HICREN Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ningbo-hicren-biotechnology-co

- Industry: Medical Devices & Equipment
- Headquarters: Ningbo, China
- Website: www.hicren.com
- Latest round: Series A (Jul 17, 2018)
- Investors on record: 1

## About

Based in Ningbo, China, and established in 2011, Ningbo HicRen Biotechnology Co.,Ltd. is a medical device company that provides vertebroplasty instruments. The company has 5,116 square meters headquarters floors area, and 800 square meters of purification workshops. It has 184 patents. As of June 2023, it has 15 class II and 8 class III NMPA medical device registration certifications, and 7 CE certifications. In 2021, it established a subsidiary, Sino-Europe Microbotics (shanghai) Co., Ltd. In June 2025, Ningbo HICREN Biotechnology Co., Ltd. raised an undisclosed amount in venture funding from new investor CS Capital. The company provides minimally invasive orthopedics products, which can be divided into verterbroplasty series, spinal fixation series, and surgical devices and consumables series. The verterbroplasty series include percutaneous curved kyphoplasty systems (PCKP), percutaneous curved vertebroplasty systems (PCVP), percutaneous vertebroplasty system (PVP), percutaneous kyphoplasty systems (PKP), and spinal bone cement. Spinal fixation series include minimally invasive posterior thoracolumbar screw-rod fixation systems, anterior cervical plate systems, open posterior thoracolumbar screw-rod fixation systems, minimally invasive posterior thoracolumbar vertebral augmentation screw-rod fixation systems, cervical interbody fusion cage, and lumbar interbody fusion cage. And surgical devices and consumables series include disposable endoscopic electrode, disposable pulse irrigator, and arthroscopic shaver systems. Those products can be used in the orthopaedic treatment.

The company generates revenue by manufacturing and selling NMPA- and CE-certified orthopedic surgical devices to hospitals and medical institutions domestically and internationally.

The company plans to use recent funding to accelerate core technology R&D, upgrade product iterations, and expand its talent pool. It also intends to further industrialize its tethered tourism aerial system and enhance its minimally invasive surgical portfolio.

## Funding rounds

- Series A, Jul 17, 2018 — GP Capital

## Investors

- GP Capital (https://capitalatlas.ai/funds/gp-capital) — Series A